Researchers in this study proved efficacy to be “comparable” for curcumin and omeprazole, a proton pump inhibitor.

In this double-blind, randomised trial, researchers evaluated the efficacy of curcumin compared with omeprazole for managing functional dyspepsia. 206 patients were treated with curcumin, omeprazole, or curcumin plus omeprazole. There was significant improvement in the three groups. No significant differences among the three groups related to symptom improvement were recorded. Synergism was not reported between omeprazole and curcumin.

The study was conducted in Thai traditional medicine hospitals, district hospitals, and university hospitals in Thailand. Participants included had a diagnosis of functional dyspepsia. Intervention included curcumin alone (C), omeprazole alone (O), or curcumin plus omeprazole (C+O). The combination group patients received two capsules of 250 mg curcumin four times daily and one capsule of 20 mg omeprazole once daily for 28 days.

The severity of Dyspepsia Assessment (SODA) score was used to measure the functional dyspepsia symptoms on days 28 and 56. Secondary outcomes included adverse events and serious adverse events.

Key results of the study are:

• One hundred fifty-one participants completed the study.
• Demographic data, clinical characteristics and baseline dyspepsia scores were comparable between the three groups.
• There were Significant improvements in SODA scores on day 28 in pain (−4.83, –5.46 and −6.22), non-pain (−2.22, –2.32 and −2.31) and satisfaction (0.39, 0.79 and 0.60) categories for the C+O, C, and O groups, respectively.
• On day 56, these improvements were enhanced in pain (−7.19, –8.07 and −8.85), non-pain (−4.09, –4.12 and −3.71) and satisfaction (0.78, 1.07, and 0.81) categories in three groups.
• No significant differences or serious adverse were reported.

Concluding further, this study found the presence of comparable efficacy between Curcumin and omeprazole for functional dyspepsia.

We found no obvious synergistic effect between curcumin and omeprazole, they noted.

Reference:

Kongkam P, et al Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double-blind controlled trial BMJ Evidence-Based Medicine Published Online First: 11 September 2023. doi: 10.1136/bmjebm-2022-112231

The findings stemmed from a multi-state investigation of seven sepsis cases transmitted during blood transfusions. Samples collected between 2018 and 2022 led researchers to platelet collection products made by the company at a plant in Puerto Rico. Ultimately, the facility was the “most probable” source of the cases, according to the report in the CDC’s Emerging Infectious Diseases journal.

Bacterial contamination of platelet components commonly occurs during blood collection and typically involves a single identified species of bacteria. But “multiple episodes” of different bacteria contamination “with identical bacterial species in platelet components across different states is exceedingly rare, suggesting a possible common source of contamination,” the researchers wrote.

Continue to STAT+ to read the full story…

The company said the agency did not raise concerns about the clinical trial data, safety or label for lebrikizumab, a monoclonal antibody for treatment of atopic dermatitis, or eczema.

The company said it will work with the manufacturer and the FDA to address the issues cited by the regulator in its so-called complete response letter.

A spokesperson for Lilly declined to provide more details on the findings of the FDA and the contract manufacturer.

Lebrikizumab was one of the five treatments that Eli Lilly was hoping to launch this year. The others include donanemab to treat Alzheimer's disease and tirzepatide for obesity.

It had sought approval for lebrikizumab based on three studies involving over 1,000 patients with moderate-to-severe eczema who were unable to control their symptoms with topical medicines or other systemic treatments.

Analysts, on average, estimate lebrikizumab to generate $1.64 billion in sales in 2026, according to LSEG data.

Atopic dermatitis has multiple treatments available, including those by AbbVie and Pfizer as well as some generic drugs like cetirizine

Read also: Eli Lilly settles whistleblower lawsuit over manufacturing problems

The Company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, Brimonidine Tartrate Ophthalmic Solution, 0.1%, Guanfacine Extended-Release Tablets USP, 1 mg, 2 mg, 3 mg, and 4 mg, Erythromycin Tablets USP, 250 mg and 500 mg, Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg.

Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg of Upsher-Smith Laboratories, LLC., is to manage the symptoms of psychotic disorders and treatment of schizophrenia, control nausea and vomiting, relief of restlessness and apprehension before surgery, acute intermittent porphyria, adjunct in the treatment of tetanus, to control the manifestations of the manic type of manic-depressive illness and for relief of intractable hiccups.

Brimonidine Tartrate Ophthalmic Solution, 0.1% with the brand name Alphagan P Ophthalmic Solution is from the innovator AbbVie, Inc. The medication is indicated to lower elevated intraocular pressure (IOP) in patients suffering with open-angle glaucoma or ocular hypertension.

Guanfacine Extended-Release Tablets USP, 1 mg, 2 mg, 3 mg, and 4 mg by Takeda Pharmaceuticals U.S.A., Inc. and with brand name Intuniv Extended-Release Tablets is indicated for individuals suffering from Attention Deficit Hyperactivity Disorder (ADHD). The tablets can be used alone or alongside stimulant medications.

Erythromycin Tablets USP, 250 mg and 500 mg by Azurity Pharmaceuticals, Inc. is for treatment of various infections caused by certain microorganisms.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5% by AbbVie,Inc. is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The brand name for the product is Combigan Ophthalmic Solution.

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg with the brand name Librax Capsules by Bausch Health US, LLC. are indicated to control emotional and physical factors that can cause gastrointestinal disorders. These capsules may also be used as additional treatments to help in peptic ulcer and in irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.

Read also: Alembic Pharma successfully completes ANVISA, Brazil GMP audit for API-III facility at Karakhadi

STOCKHOLM (AP): Two scientists won the Nobel Prize in medicine on Monday for discoveries that enabled the creation of mRNA vaccines against COVID-19 that were critical in slowing the pandemic — technology that’s also being studied to fight cancer...

IT IS true that hormone imbalances can be associated with many problems, such as period problems, unwanted hair growth, fertility struggles, weight gain, and even difficulty sleeping. If you are experiencing these symptoms, you should talk to your...

PAHO Director meets with President of Argentina to discuss regional vaccine development and other priority health issues

Cristina Mitchell

3 Oct 2023

View the full post Towards a National Coordinating Mechanism to address Gender-Based Violence on NOW Grenada.

The presenter confessed to wondering: ' what's the point?' and thinking: 'there is obviously one way to make this stop' , while describing how 'horrific' the menopause can be